India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Novo Nordisk (NYSE:NVO)

India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Novo Nordisk (NYSE:NVO)

India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks. Importance Rank:  1

India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top

Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.

Factbox-Indian drugmakers flood market with cheaper versions of Novo’s Ozempic, Wegovy - Regional Media News

March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%. The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands. Analysts expect …

India Gets Cheaper Ozempic Alternatives as Pharma Giants Launch Generics

India’s pharmaceutical market is entering a pivotal moment for diabetes and weight-loss treatment. Several leading drugmakers—Sun Pharma, Dr. Reddy’s Laboratories, Glenmark, and Zydus Lifesciences—have rolled out generic semaglutide injections after patent protections expired locally on the molecule behind blockbuster drugs like Ozempic and Wegovy. The headline isn’t just competition; it’s cost. These new launches could dramatically expand acces…